Malaria is a disease contracted by over 200 million people each year, mostly in developing countries. The primary causative agent, Plasmodium falciparum (P. falciparum) has shown increased resistance to existing drugs, hence new treatments are needed quickly. To this end we performed a high-throughput systems-level analysis, mapping existing FDA drugs with the potential for repurposing against targets from the P. falciparum structural proteome. The resulting P. falciparum drugome (P.falciparum-drugome) was used to prioritize potential new anti-malaria candidate targets and highlight some novel FDA approved drugs that have apparent anti-malaria effects for possible use as multi-target therapeutics.
INTRODUCTION
The emerging field of systems pharmacology is changing the way we think about drugs. The traditional "one-drug one-target one-disease" paradigm has proven inadequate for drug discovery 1 ; whereas the idea of multi-target drug interactions leading to the observed phenotype The P.falciparum-drugome reveals that, of the 308 different drugs investigated, 88 drugs could potentially inhibit more than one P. falciparum protein. This is advantageous because multi-target therapeutics can be more efficacious and less vulnerable to adaptive resistance 17 . Highly connected drugs have the potential to inhibit a large number of different P. falciparum proteins simultaneously, a literature research of the highly connected drugs also support this hypothesis.
The top nine highly connected drugs are further revised. With 76 cross-fold connections, alitretinoin, a drug used to treat cutaneous lesions in patients with Kaposi's sarcoma, is the most highly connected drug. Alitretinoin, also called 9-cis-retinoic acid, is a metabolite of vitamin A.
It is well known that supplementation with vitamin A can significantly reduce the malaria infection and decreases the mortality of infected young children 18 . With 70 cross-fold connections, methotrexate, an anti-cancer drug, is the second most highly connected drug. Note that although serum albumin is listed as one intended target of methotrexate, this drug has not actually been crystallized with serum albumin in PDB, so this does not account for its high connectivity. Several groups have shown that methotrexate is extremely effective against P. falciparum in vitro 19 . Nzila group has tested methotrexate in four murine species, however, none of them were susceptible to methotrexate. Noteworthy that they also tested the efficacy of pyrimethamine, a known antimalarial drug, in combination with folic acid in Plasmodium berghei, a murine plasmodium species that highly similar to human parasite P. falciparum, and data indicate that folic acid does not influence pyrimethamine efficacy, which suggests that the murine plasmodium, P. berghei, may not transport folate. Since methotrexate utilizes folate receptor/transport to gain access to cells, its lack of efficacy against the four tested murine malaria species may be the result of inefficiency of drug transport 20 . It is worth mentioning that a phase I trial in Kenyan adult healthy volunteers was carried out, and result suggests that lowdose methotrexate had an acceptable safety, but methotrexate blood levels did not reach the desirable concentration to clear malaria infection, further dose finding is necessary 21 . With 63 different cross-fold connections, levothyroxine, a drug used to treat hypothyroidism, is the third most highly connected drug. Further investigation revealed that it was the structure of levothyroxine bound in the binding site of serum albumin that was determined to be significantly similar to 44 of the 63 different P. falciparum binding sites. As a non-specific binder of steroid hormones and a transport protein for various fatty acids, serum albumin is known to be a highly promiscuous protein 22 . To our knowledge, there is no report of levothyroxine having any effect on malaria. Besides, the forth highly connected drug, raloxifene, a drug used to prevent and treat osteoporosis and breast cancer in women, also hasn't been reported affecting malaria. The fifth highly connected drug, estradiol, is a sex hormone. In the past few years, evidence has accumulated that many hormones, especially the sex steroids, can influence the immune system and thus susceptibility for diseases caused by protozoan parasites 23 . An in vivo experiment shows that estradiol can decreases parasitemia, but increases the incidence of cerebral malaria and the mortality in P. berghei infected mice 24 . Although the complete mechanism has not yet been unraveled, there is still an evidence that estradiol has effect on P. falciparum proteins.
It is worth to notice that drugs with an above-average number of connections are either antibacterial drugs or human affecting drugs ( Figure 6 ). Although the whole distribution increased slightly, part of the antibacterial drugs are connected to a larger number of different P. falciparum proteins than antiviral drugs, making these certain antibacterial drugs the most likely candidates against malaria assuming the goal is to impact as many targets as possible in the battle to overcome resistance through mutation.
The sixth highly connected drug, fusidic acid, is a bacteriostatic antibiotic. Many studies suggest that fusidic acid has potential activity against malaria 25 , Johnson et al. shows that fusidic acid inhibited the growth of P. falciparum erythrocytic stages with immediate death effect 26 . Other antibacterial drugs whose connections are above average are rifampin, trimethoprim and tetracycline. The antimalarial activity of rifampin was confirmed with P. falciparum in vitro 27 , and a combination with other 2 drugs was verified safe and efficacious for treating malaria in murine model 28 . Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase, and World Health Organization (WHO) guidelines for the treatment of malaria recommend a combination of trimethoprim and sulfamethoxazole as prophylaxis for HIV-infected patients to protect against malaria 29 . Tetracycline is a broad spectrum antibiotic, and has also been recommended by WHO as second-line antimalarial treatment when combined with artesunate or quinie 29 .
To further investigate the effects of gene encoding P. falciparum proteins in metabolism, we here use a genome-scale flux-balanced metabolic network model 30 . We revised top 9 highly connected drugs and the P. falciparum proteins they connected to which are predicted essential for growth in the unconstrained metabolic network of P. falciparum. All of these 9 drugs are predicted bind at least one essential P. falciparum protein, indicating the highly connected drugs have high potential to be antimalarial drugs.
The concept of "synthetic lethality" -some genes may not essential on their own, but are lethal if deleted simultaneously -sheds new light on drug development 31 . The most interesting thing is that, in the P. falciparum metabolic network, they predict 16 gene pairs that have synthetic lethality, and one of them occurs in alitretinoin, levothyroxine and mifepristone. Another pair of the synthetic lethal genes is connected to different drugs, making it possible to use these drugs as combination therapy.
According to these experimental supports, it is highly believed that with the help of our discovery the representative drugs listed in our P.falciparum-drugome are worth exploring and testing thoroughly.
DISCUSSION
Existing drug-target networks are typically constructed from either annotated drug-target pairs or transference of chemical properties. Here we present our second (the first was the TB-drugome) high throughput structural-based proteome-wide drug-target network, that of P. falciparum -the P.falciparum-drugome. By using Food and Drug Administration (FDA) approved drugs we present the raw data for possible repurposing strategies, since these drugs are assumed safe. By presenting the drug target interaction network based on binding site similarity across much of the P. falciparum proteome we provide raw data on possible new targets for these drugs where the hubs represent the best opportunities to combat resistance. Experimental support exists for some of our theoretical findings and a variety of putative new targets and repurposing opportunities are presented in the supplemental materials. Simultaneously we are beginning to examine the TBand P. falciparum drugomes against the emergent human drugome. This will be the subject of a future publication. Likewise, we are working on a workflow software system that will enable others to simply compute drugomes or update existing drugomes as new drugs and putative targets become available.
It is worth mentioning that Yuan et al used a high-throughput chemical screening approach, and identified 32 highly active compounds 32 33 . The compounds they provide are different from the drugs in our drugome, mainly because most of the compounds are not approved drugs or have no co-crystallized structure as yet. While chemical high throughput screening will find compounds with direct antimalarial effect, some of the most promising candidates for combined therapy may be missed. For example, the highly connected drug in our drugome, rifampin, which is proven safe and efficacious for treating malaria in a murine model when combined with isoniazide and ethambutol, but not alone 28 , does not exist in either Yuan's work or Malaria Box.
Notwithstanding there are some unavoidable limitations to our approach. First, although the genome of P. falciparum is sequenced 34 , structural coverage is only 2.1% from experimental structure and 12.5% when homology models are included. Models may be of limited accuracy, being modeled from single chains, missing many protein-drug interactions that occur at the interfaces between tertiary units of the protein and only observed if the quaternary structure is modeled. Even more limiting is the bias in the PDB from which experimental structures are drawn and models inferred. Many drug targets, notably membrane proteins, are underrepresented in the PDB. While the number of FDA approved drugs rises slowly the structural coverage of a variety of proteomes, including human is increasing more rapidly and will only see this type of high throughput technique improve, especially when used with emergent methods from systems pharmacology.
MATERIALS AND METHODS

Structural coverage of the P. falciparum proteome
There are 5491 protein-encoding genes in the P. falciparum proteome 34 To maximize coverage of the P. falciparum proteome we also include homology models deposited in ModBase 35 , a database of annotated comparative protein structure models and associated resources. This database contains over 20 thousands homology models for the entire P. falciparum proteome since ModBase has several models for each protein sequence; a model is considered reliable if its Model score (GA341) is greater than 0.7 and its ModPipe Protein Quality Score (MPQS) is greater than 1.1 (http://modbase.compbio.ucsf.edu/modbase-cgi/ display.cgi?type=help&server=modbase). Employing these thresholds, there are 1236 reliable homology models (Oct 18, 2011), and the total structural coverage of the P. falciparum proteome is 12.5%. As indicated in the Discussion, only a single chain of each homology model is available, rather than the entire biological unit.
Identification of FDA-approved drug binding sites
The DrugBank database 36 combines detailed drug and target information where known (http:// www.drugbank.ca/). Drugs approved by the U.S. Food and Drug Administration (FDA) are taken from DrugBank and all the nutraceuticals removed. We use InChI keys to map these FDAapproved drugs to ligands in the PDB to find the associated co-crystalized structures. After removing non-protein structures, such as DNA, RNA and associated complexes, there are 308 FDA-approved drugs with 1423 drug-protein binding sites (Dec 6, 2011). We compare 1423 drug binding sites against 1569 P. falciparum proteins, including both experimental structures and homology models. The entire structure of each P. falciparum protein is used to avoid missing alternative binding sites on any given P. falciparum protein. A p-value is reported to measure the similarity of the binding sites for each pair.
Comparison of ligand binding sites using SMAP
Comparison of global protein structures using FATCAT
FATCAT (Flexible structure AlignmenT by Chaining Aligned fragment pairs allowing Twists) 37 is an approach for flexible protein structure comparison. The Java version of FATCAT was downloaded from the RCSB PDB website and run locally (http://pdbx.org/jfatcatserver/ download.jsp).
In order to detect only remote similarities between the P. falciparum proteins and drug binding site proteins, that is, those which cannot be identified through global structure comparison, we exclude those pairs identified by FATCAT where the p-value was less than 0.5.
Visualization of the protein-drug interaction network
We use yEd from yWorks to visualize the protein-drug interaction network (http:// www.yworks.com/en/products_yed_about.html). A node represents a P. falciparum structure or a drug ligand. If a P. falciparum structure and a drug binding site have similar binding sites, and their global structures are dissimilar (according to the criteria outlined above), we place an edge between the P. falciparum structure and the associated drug.
GO term enrichment analysis
To evaluate the functional relationships between target proteins of each highly connected drug, we use DAVID (Database for Annotation, Visualization and Integrated Discovery) 38 to perform a GO term enrichment, since DAVID provides a comprehensive set of functional annotation tools for investigators to understand biological meaning behind large list of genes. DAVID uses a modified Fisher Exact p-value to measure the enrichment of each GO term. The smaller a pvalue is, the more enriched this GO term is.
We use the UniProt accessions of each target protein and associated drug binding sites to do the GO term enrichment. For each highly connected drug, we establish the GO term enrichment of the associated P. falciparum structures. In general terms, if these targets are in diverse pathways, this drug may hold promise for a multi-target treatment regime, with particular emphasis on avoiding resistance. Alternatively, if these targets are enriched in a specific pathway, this means the drug have the potential to treat the specific disease without side effects. ! Figure 6 . A ranking of FDA approved drugs according to the number of targets to which the drug is assumed to bind. Table S1 . Information about the approved drug binding sites used in the P.falciparum-drugome.
Supporting Information
This file contains information about the 308 approved drugs that were identified in the PDB. For each drug, its name, PDB ligand code, isomeric SMILES string and known targets are listed, and the PDB codes of the protein structures with which it has been crystallized are given. Table S2 . Cross-fold drug-target pairs in the P.falciparum-drugome (for solved P. falciparum structures only). This file contains a list of the cross-fold drug-target pairs with a SMAP P-value <1.0e-5, for solved P. falciparum structures only. For each pair, information about the drug and target structures is given, as well as the corresponding SMAP P-value (indicating the significance of the binding site similarity) and AutoDock Vina score (from docking the drug into the predicted binding site in the P. falciparum protein). Table S3 . Cross-fold drug-target pairs in the P.falciparum-drugome (for P. falciparum homology models only). This file contains a list of the cross-fold drug-target pairs with a SMAP P-value <1.0e-5, for homology models of P. falciparum proteins only. For each pair, information about the drug and target structures is given, as well as the corresponding SMAP P-value (indicating the significance of the binding site similarity) and AutoDock Vina score (from docking the drug into the predicted binding site in the M.tb protein). Table S4 . Information about the solved P. falciparum structures used in the P.falciparumdrugome. This file contains information about the P. falciparum proteins with solved structure(s) in the RCSB PDB that were used in the P.falciparum-drugome. For each protein, the gene name, protein name and corresponding PDB codes are given.
